Analysts Point To Abbott Laboratories (NYSE: ABT) Growth In The Future

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Recently, Yahoo Finance discussed the stock, revealing that Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

As a NYSE listed company, ABT falls under the Healthcare sector while operating within the Medical Devices industry segment. The current market capitalization of Abbott Laboratories is $194.37B. A total of 4.56 million shares were traded on the day, compared to an average of 5.72M shares.

In the most recent transaction, Salvadori Daniel Gesua Sive sold 963 shares of ABT for 118.50 per share on Mar 01 ’24. After the transaction, the EXECUTIVE VICE PRESIDENT now owns 125,697 company shares. In a previous transaction on Mar 01 ’24, ALLEN HUBERT L sold 853 shares at 118.50 per share. ABT shares that EXECUTIVE VICE PRESIDENT owns now total 184,806.

Among the insiders who sold shares, Morrone Louis H. disposed of 801 shares on Mar 01 ’24 at a per-share price of $118.50. This resulted in the EXECUTIVE VICE PRESIDENT holding 62,968 shares of ABT after the transaction. In another insider transaction, Earnhardt Lisa D sold 694 shares at $118.50 per share on Mar 01 ’24. Company shares held by the EXECUTIVE VICE PRESIDENT now total 84,314.


Investors prefer companies that pay dividends because dividends generate immediate cash flow and indicate a positive outlook. Abbott Laboratories pays an annual dividend of $2.08, resulting in a dividend yield of 1.86%, and it has a price to earnings (P/E) ratio of 34.30. ABT’s most recent ex-dividend date was 4/12/2024 when it declared a $0.55 quarterly dividend that was paid in cash on 5/15/2024. Previously, the company paid the dividend on 2/15/2024 with an ex-dividend date of 1/11/2024. The ABT stock dividend was $0.55 per share in cash.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, ABT has a high of $121.64 and a low of $89.67.

As of this writing, ABT has an earnings estimate of $0.96 per share for the current quarter. EPS was calculated based on a consensus of 20 estimates, with a high estimate of $1.01 per share and a lower estimate of $0.94. The company reported an EPS of $1.14 in the last quarter, which was 3.60% higher than expectations of $1.1.

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ABT’s latest balance sheet shows that the firm has $10.25B in Cash & Short Term Investments as of fiscal 2021. There were $19.01B in debt and $13.11B in liabilities at the time. Its Book Value Per Share was $22.26, while its Total Shareholder’s Equity was $36.02B.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ABT is Buy with a score of 4.44.

Most Popular

Related Posts